![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 7 of 7. This is the beginning of the thread.
Posted by Neal on May 13, 2001, at 1:58:51
Lilly at the present time is already heavily investing their big bucks in what they hope is the next blockbuster antidepressant, duloxetine.
So, what is it, how are the trials coming, is it another SSRI?
Posted by SLS on May 13, 2001, at 11:12:09
In reply to Duloxetine Questions, posted by Neal on May 13, 2001, at 1:58:51
Hi Neal.
> Lilly at the present time is already heavily investing their big bucks in what they hope is the next blockbuster antidepressant, duloxetine.
>
> So, what is it, how are the trials coming, is it another SSRI?
Someone mentioned this in a previous thread. This is news to me.Duloxetine is a SNRI (serotonin-norepinephrine reuptake inhibitor). It inhibits the reuptake of both serotonin and norepinephrine.
When I first heard about duloxetine a number of years ago, I was looking forward to seeing its development. However, my unreliable memory recalls encountering something on Medline that gave me the impression that it is not a very promising compound for treating depression. I hope they were wrong.
- Scott
Posted by stjames on May 13, 2001, at 16:59:47
In reply to Duloxetine Questions, posted by Neal on May 13, 2001, at 1:58:51
NEW LILLY DRUG EFFECTIVE AGAINST MAJOR DEPRESSION
With Eli Lilly's patent on the blockbuster antidepressant fluoxetine
(Prozac) set to expire, the firm on Monday released late-stage data
showing that a new product in its pipeline, duloxetine, safely and
effectively treats depression.
http://psychiatry.medscape.com/37485.rhtml?srcmp=psy-051101
< a href="http://psychiatry.medscape.com/37485.rhtml?srcmp=psy-051101" >
Read it Here< /a >
Posted by SLS on May 14, 2001, at 7:52:28
In reply to Re: Duloxetine Questions/late-stage data, posted by stjames on May 13, 2001, at 16:59:47
Hi.
From the news brief:
"The company said that 50% of duloxetine-treated patients achieved remission of depression symptoms, versus 29.5% of patients receiving placebo."
I don't want to rain on anyone's parade, and I don't doubt that duloxetine will effectively treat some people who have not responded to any other drug, but 50% versus 30% sucks. Well, I should say that 50% sucks if the same criteria were used for this study that have been used in the past for the same protocols.
I would like to see duloxetine approved. The more tools that are available to me, the greater the likelihood that I will find an effective treatment and start a new life in the world of the living.
What do others think of 50% duloxetine versus 30% placebo?
- Scott
Posted by shelliR on May 14, 2001, at 12:18:46
In reply to Re: Duloxetine Questions/late-stage data, posted by SLS on May 14, 2001, at 7:52:28
> Hi.
>
> From the news brief:
>
> "The company said that 50% of duloxetine-treated patients achieved remission of depression symptoms, versus 29.5% of patients receiving placebo."
>
> I don't want to rain on anyone's parade, and I don't doubt that duloxetine will effectively treat some people who have not responded to any other drug, but 50% versus 30% sucks. Well, I should say that 50% sucks if the same criteria were used for this study that have been used in the past for the same protocols.
>
> I would like to see duloxetine approved. The more tools that are available to me, the greater the likelihood that I will find an effective treatment and start a new life in the world of the living.
>
> What do others think of 50% duloxetine versus 30% placebo?
>
>
> - ScottScott, there are two things about this study that I find even more interesting than the 50% vs 30% duloxetine vs placebo results.
1) In addition to testing dulonetine against a placebo, they also tested it against paroxetine (paxil). Why didn't they test it against prozac!
2) Much more interesting to me: In the Reuters Medical News, they report that no figure was given for those treated with paroxetine. Why not? Leads one to believe that those treated with paxil may have had much better outcomes than with dulonetine. Just a guess. I don't get how a drug company can put out a news release on a study and omit the results of half of it.
Am I missing something, or am I just naive?
shelli
Posted by Paige on May 14, 2001, at 17:53:58
In reply to Re: Duloxetine Questions/late-stage data » SLS, posted by shelliR on May 14, 2001, at 12:18:46
Hi Shellii-I am going out on the limb here, but if they tested
it against Prozac and the new "weekly" prozac is
all they have to market (due to the expired patent
on the daily Prozac)and they are marketing the weekly
one fast and hard, why even attempt to ruin its
chances right now. This is also a way to boost
the chances of duloxetine wouldn't you think? Or am
I being naive?? I was just trying to do the math
and the marketing and I'd say you'd have to be careful
if it turned out to be a real good one, so test against
something other than the one which is doing just fine...
Prozac. I know it is skeptical, and I hope I
have made some sense, but more importantly, I hope
they find something that really helps certain people
like myself, nothing seems to work and I feel
like I'll dehydrate from all the crying pretty soon.
Not trying to burst the bubble, just really hope there
is a bubble, several of them and that none burst.
Paige
Posted by Fred Potter on May 14, 2001, at 22:29:40
In reply to Re: Duloxetine Questions/late-stage data » shelliR, posted by Paige on May 14, 2001, at 17:53:58
50% vs 30% isn't very impressive nonetheless. The question is, does it therefore have a 50% or 20% success rate? I would say this is a question of relativity. The patient has a 50% success rate, but the drug has a 20% success rate.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.